From: rpautrey2 on

Medicinal marijuana effective for neuropathic pain in HIV
August 06, 2008


In a double-blind, placebo-controlled clinical trial to assess the
impact of smoked medical cannabis, or marijuana, on the neuropathic
pain associated with HIV, researchers at the University of California,
San Diego School of Medicine found that reported pain relief was
greater with cannabis than with a placebo. The study, sponsored by the
University of California Center for Medical Cannabis Research (CMCR)
based at UC San Diego, will be published on line, August 6 in the
journal Neuropsychopharmacology.


Led by Ronald J. Ellis, M.D., Ph.D., associate professor of
neurosciences at UCSD School of Medicine, the study looked at 28 HIV
patients with neuropathic pain not adequately controlled by other pain-
relievers, including opiates. They took part in the controlled study
as outpatients at the UCSD Medical Center. The proportion of subjects
achieving pain reduction of 30 percent or more was greater for those
smoking cannabis than those smoking the placebo.

"Neuropathy is a chronic and significant problem in HIV patients as
there are few existing treatments that offer adequate pain management
to sufferers," Ellis said.

"We found that smoked cannabis was generally well-tolerated and
effective when added to the patient's existing pain medication,
resulting in increased pain relief."

Each trial participant participated in five study phases over seven
weeks. During two five-day phases, randomly selected participants
smoked either cannabis or placebo cigarettes made from whole plant
material with cannabinoids (the psychoactive compound found in
marijuana) removed, both provided by the National Institute on Drug
Abuse. Outcome was tested by standardized tests measuring analgesia
(lessened pain sensation), improvement in function and relief of pain-
associated emotional distress.

Using verbal descriptors of pain magnitude, cannabis was associated
with an average reduction of pain intensity from 'strong' 'to mild-to-
moderate' in cannabis smokers, according to Ellis. Also, cannabis was
associated with a sizeable (46% versus 18% for placebo) proportion of
patients reporting clinically meaningful pain relief.

The study's findings are consistent with and extend other recent
research supporting the short-term efficacy of cannabis for
neuropathic pain, also sponsored by the CMCR.

"This study adds to a growing body of evidence that indicates that
cannabis is effective, in the short-term at least, in the management
of neuropathic pain," commented Igor Grant, M.D., professor of
psychiatry and director of the CMCR.

Source: University of California - San Diego






This news is brought to you by PhysOrg.com
http://www.physorg.com/news137233579.html